Taken together, these results show that ICB treatment of MMR-d colon cancer increases the presence of activated, cytotoxic and proliferating γδ T cells at the tumour site, especially when these cancers are B2M-deficient, highlighting γδ T cells as effectors of ICB treatment within this context. Here, B2M is linked to cancer.